Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25678461 | 0.74 | CCR1 (0.33) | DYRK1A | |
| SCHEMBL12125322 | 0.71 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL402254 | 0.69 | MAP4K4 (0.47) | MAP4K4DYRK1A | |
| SCHEMBL1154966 | 0.69 | — | — | |
| SCHEMBL12405880 | 0.69 | MAP4K4 (0.60) | MAP4K4 | |
| SCHEMBL15760228 | 0.69 | MAP4K4 (0.40) | MAP4K4DYRK1A | |
| SCHEMBL12125310 | 0.69 | — | — | |
| SCHEMBL12395329 | 0.69 | — | — | |
| SCHEMBL12395129 | 0.68 | EGFR (0.41) | MAP4K4 | |
| SCHEMBL25583460 | 0.68 | DYRK1A (0.36) | CCNKCDK4CCNCCDK2CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ENPP1, ENPP3, ENPEP | MAP4K4 2955/4885CCNK 4306/4885CDK4 3635/4885 |
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ENPP1, ENPP3, PNKP | MAP4K4 2868/4885CCNK 4192/4885CDK4 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.